Header Logo

Connection

SUSAN HILSENBECK to Receptors, Estrogen

Back to Details
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Receptors, Estrogen.
SUSAN HILSENBECK
Connection Strength
2.161
Receptors, Estrogen
  1. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
    View in: PubMed
    Score: 0.119
  2. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
    View in: PubMed
    Score: 0.101
  3. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.098
  4. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.093
  5. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994 Sep 01; 74(5):1601-6.
    View in: PubMed
    Score: 0.089
  6. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121.
    View in: PubMed
    Score: 0.073
  7. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.
    View in: PubMed
    Score: 0.070
  8. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
    View in: PubMed
    Score: 0.066
  9. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40.
    View in: PubMed
    Score: 0.063
  10. Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.
    View in: PubMed
    Score: 0.060
  11. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55.
    View in: PubMed
    Score: 0.057
  12. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.
    View in: PubMed
    Score: 0.055
  13. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
    View in: PubMed
    Score: 0.051
  14. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s.
    View in: PubMed
    Score: 0.049
  15. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
    View in: PubMed
    Score: 0.049
  16. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
    View in: PubMed
    Score: 0.046
  17. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78.
    View in: PubMed
    Score: 0.045
  18. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.045
  19. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004 May 15; 64(10):3525-32.
    View in: PubMed
    Score: 0.043
  20. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res. 2024 02 05; 26(1):23.
    View in: PubMed
    Score: 0.043
  21. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
    View in: PubMed
    Score: 0.042
  22. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
    View in: PubMed
    Score: 0.041
  23. Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol. 2002 Sep; 82(1):7-18.
    View in: PubMed
    Score: 0.039
  24. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022 01; 15(1):3-10.
    View in: PubMed
    Score: 0.036
  25. Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation. J Endocrinol. 2001 Oct; 171(1):75-83.
    View in: PubMed
    Score: 0.036
  26. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.
    View in: PubMed
    Score: 0.035
  27. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9.
    View in: PubMed
    Score: 0.033
  28. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.032
  29. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.
    View in: PubMed
    Score: 0.028
  30. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.028
  31. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res. 2017 07 15; 77(14):3802-3813.
    View in: PubMed
    Score: 0.027
  32. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
    View in: PubMed
    Score: 0.027
  33. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.026
  34. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
    View in: PubMed
    Score: 0.023
  35. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.022
  36. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
    View in: PubMed
    Score: 0.020
  37. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804.
    View in: PubMed
    Score: 0.020
  38. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243.
    View in: PubMed
    Score: 0.019
  39. ?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84.
    View in: PubMed
    Score: 0.018
  40. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
    View in: PubMed
    Score: 0.018
  41. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
    View in: PubMed
    Score: 0.017
  42. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.017
  43. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96.
    View in: PubMed
    Score: 0.017
  44. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
    View in: PubMed
    Score: 0.016
  45. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.
    View in: PubMed
    Score: 0.016
  46. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
    View in: PubMed
    Score: 0.015
  47. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21.
    View in: PubMed
    Score: 0.014
  48. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
    View in: PubMed
    Score: 0.014
  49. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40.
    View in: PubMed
    Score: 0.013
  50. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.013
  51. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15; 107(4):696-704.
    View in: PubMed
    Score: 0.013
  52. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
    View in: PubMed
    Score: 0.012
  53. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.
    View in: PubMed
    Score: 0.012
  54. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.011
  55. Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8.
    View in: PubMed
    Score: 0.011
  56. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80.
    View in: PubMed
    Score: 0.010
  57. Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35.
    View in: PubMed
    Score: 0.009
  58. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001 Jun; 7(6):1739-42.
    View in: PubMed
    Score: 0.009
  59. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
    View in: PubMed
    Score: 0.008
  60. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
    View in: PubMed
    Score: 0.008
  61. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.006
  62. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996 May 01; 88(9):601-6.
    View in: PubMed
    Score: 0.006
  63. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.
    View in: PubMed
    Score: 0.006
  64. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994 Feb 28; 77(1):25-32.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.